J. Dong

发表

Erratum: Does gut hormone PVY3-36 decrease food intake in rodents? (Nature (2004) 430 (165) DOI:10.1038/nature03019)

D. Allison, R. Seeley, M. Tschöp, 2004 .

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

S. Melmed, I. Shimon, J. Taylor, 1997, The Journal of clinical investigation.

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

S. Melmed, M. Culler, S. Ren, 2003, The Journal of clinical endocrinology and metabolism.

Physiology: Does gut hormone PYY3–36 decrease food intake in rodents?

D. Allison, R. Seeley, M. Tschöp, 2004, Nature.

PYY3‐36 as an anti‐obesity drug target

D. Allison, R. Seeley, M. Tschöp, 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

Appetite Regulatory Peptides PYY 3-36 as an anti-obesity drug target

D. Allison, R. Seeley, M. Tschöp, 2005 .

Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH Pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor.

M. Culler, R. Datta, J. Epelbaum, 2005, Endocrinology.

Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells.

I. Shimon, H. Rubinfeld, J. Taylor, 2004, European journal of endocrinology.

The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.

J. Taylor, M. Culler, M. Pawlikowski, 2006, Life sciences.

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

J. Taylor, M. Culler, H. Dufour, 2005, European journal of endocrinology.

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.

J. Taylor, M. Culler, A. Barlier, 2005, Journal of endocrinological investigation.

Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution.

J. Taylor, T. Davis, J. Dong, 1998, The Journal of pharmacology and experimental therapeutics.

Chimeric Somatostatin–Dopamine Compounds (Dopastatins) for the Treatment of Neuroendocrine Disease

M. Culler, N. Tsomaia, J. Dong, 2017 .

Improved analogs and novel delivery systems for somatostatin octapeptides.

J. Taylor, F. Ignatious, B. Morgan, 1996, Metabolism: clinical and experimental.